GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (XCNQ:DOSE) » Definitions » Cyclically Adjusted PS Ratio

Rapid Dose Therapeutics (XCNQ:DOSE) Cyclically Adjusted PS Ratio : 20.00 (As of May. 04, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Rapid Dose Therapeutics Cyclically Adjusted PS Ratio?

As of today (2025-05-04), Rapid Dose Therapeutics's current share price is C$0.20. Rapid Dose Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Nov. 2024 was C$0.01. Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio for today is 20.00.

The historical rank and industry rank for Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

XCNQ:DOSE' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.6   Med: 17   Max: 66
Current: 13.47

During the past years, Rapid Dose Therapeutics's highest Cyclically Adjusted PS Ratio was 66.00. The lowest was 4.60. And the median was 17.00.

XCNQ:DOSE's Cyclically Adjusted PS Ratio is ranked worse than
75.64% of 505 companies
in the Biotechnology industry
Industry Median: 5.41 vs XCNQ:DOSE: 13.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rapid Dose Therapeutics's adjusted revenue per share data for the three months ended in Nov. 2024 was C$0.004. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is C$0.01 for the trailing ten years ended in Nov. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Rapid Dose Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics Cyclically Adjusted PS Ratio Chart

Rapid Dose Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 268.23 23.88 17.80 7.14 14.55

Rapid Dose Therapeutics Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.03 14.55 18.00 12.46 22.19

Competitive Comparison of Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Rapid Dose Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.20/0.01
=20.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Nov. 2024 is calculated as:

For example, Rapid Dose Therapeutics's adjusted Revenue per Share data for the three months ended in Nov. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Nov. 2024 (Change)*Current CPI (Nov. 2024)
=0.004/127.8378*127.8378
=0.004

Current CPI (Nov. 2024) = 127.8378.

Rapid Dose Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.473 0.000
201409 0.000 99.394 0.000
201412 0.000 98.367 0.000
201503 0.000 99.789 0.000
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 0.000 101.449 0.000
201703 0.000 102.634 0.000
201706 0.000 103.029 0.000
201709 0.000 103.345 0.000
201712 0.000 103.345 0.000
201809 0.000 105.636 0.000
201902 0.000 106.268 0.000
201905 0.000 107.927 0.000
201908 0.012 108.085 0.014
201911 -0.012 107.769 -0.014
202002 0.001 108.559 0.001
202005 0.000 107.532 0.000
202008 0.000 108.243 0.000
202011 0.002 108.796 0.002
202102 0.008 109.745 0.009
202105 0.010 111.404 0.011
202108 0.004 112.668 0.005
202111 0.005 113.932 0.006
202202 0.001 115.986 0.001
202205 0.001 120.016 0.001
202208 0.001 120.569 0.001
202211 0.003 121.675 0.003
202302 0.002 122.070 0.002
202305 0.002 124.045 0.002
202308 0.003 125.389 0.003
202311 0.002 125.468 0.002
202402 0.002 125.468 0.002
202405 0.003 127.601 0.003
202408 0.004 127.838 0.004
202411 0.004 127.838 0.004

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rapid Dose Therapeutics  (XCNQ:DOSE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Rapid Dose Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Dose Therapeutics Business Description

Traded in Other Exchanges
Address
1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
Executives
Mark Upsdell Director
Brian Howlett Director

Rapid Dose Therapeutics Headlines

No Headlines